Dear Readers, The I-GENE team is pleased to welcome you to the 4th issue of the I-GENE newsletter.
Join the Evo Nano team to hear about our evolvable platform for programmable nanoparticle-based cancer therapies
EU-backed researchers build state-of-the-art software that harnesses AI to design nanomedicine that fights cancer cells.
Our valued colleagues from EVO-NANO project in silico group published on-line their newest research on multi type NPs anticancer therapies …
Mixed charged functionalised gold nanoparticles proved to serve as efficient organelle specific delivery vehicles!
The school will provide an overview of the use CRISPR/Cas9 technique as a powerful tool for gene editing.
Members of the EVONANO consortium (University of Novi Sad and University of the West of England) have published most recently the results on the in silico optimization of multi component cancer nanotherapies.
It was identify as Business Ready (Market Maturity of the Innovation) and the potential of the innovation is very high
Prochimia Surfaces and their colleagues from the I-gene project are honored to invite all interested parties to the training school.
Our wide collaboration Scienfic Report on ProChimia's multi sulphonated ligands has been published on June 2020 by Nature
AuNPs charged by our ionized ligands has been just shown to exhibit anticancer activity leading selectively to death of cancerous cells.
I-GENE is a technique to erase harmful mutations in genetic diseases.
ProChimia Surfaces is proud to present new category of our products
A new class of thiolated ligands exhibiting the ultra non-fouling properties has been intorduced to our product portfolio
Read more http://evonano.eu